Abstract
INTRODUCTION The attenuated mycobacterium Bacille Calmette Guerin is widely utilized as intravesical immunotherapy for the treatment of non-muscle invasive urothelial carcinoma. At present, there is limited data on the relationship between BCG dose intensity and tumor response. This study evaluated dose-response relationship of BCG to NMIBC in vitro using urothelial carcinoma cell lines and in vivo using orthotopic mouse model.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
